Efficacy of Strictly diabetic/ diabetic Mutation?

Transcription

1 CURRICULUM VITAE FORMATO EUROPEO/ EUROPEAN FORMAT INFORMAZIONI PERSONALI/ PERSONAL INFORMATION Nome, Cognome/Name, Surname Indirizzo/Address Via, numero civico, c.a.p., città, nazione/ House number, street name, postcode, city, country Antonio La Cava 1912 Broadway, Apt. 301 Santa Monica, California USA Telefono/Telephone Fax Sito web/website Nazionalità/Nationality Luogo e data di nascita/ Place and Date of birth Italian Monza (MI), Italy December 10, 1960 ESPERIENZA PROFESSIONALE/ WORK EXPERIENCE Se dipendente CNR indicare: In ordine di data /Dates (from to) [Iniziare con le più recenti ed elencare separatamente ciascun incarico ricoperto/ Add separate entries for each relevant post occupied, starting with the most recent. ] Nome e indirizzo del datore di lavoro / Name and address of employer Tipo o settore di attività / Type of business or sector Funzione o posto occupato / Occupation or position held N. MATRICOLA QUALIFICA LIVELLO 2009-present: Director of the University of California Los Angeles (UCLA) Center of Excellence for the Federation of Clinical Immunology Societies 2010-present: Professor, Division of Rheumatology, Department of Medicine, UCLA : Associate Professor, Division of Rheumatology, Department of Medicine, UCLA 2005-present: Director of the Lupus Research Laboratory at UCLA : Assistant Professor, Division of Rheumatology, Department of Medicine, UCLA : Research Associate, Department of Immunology, The Scripps Research Institute, La Jolla, California : Postgraduate Research Immunologist, Department of Medicine, University of California San Diego : Postdoctoral Fellow, Department of Cellular and Molecular Biology and Pathology, School of Medicine, "Federico II" University of Naples, Italy University of California Los Angeles 1000 Veteran Ave , Los Angeles, California , USA University, School of Medicine Professor Page 1 - Curriculum vitae

2 Principali mansion e responsabilità / Main activities and responsibilities Research, Teaching, Administration ISTRUZIONE E FORMAZIONE / EDUCATION AND TRAINING In ordine di data /Dates (from to) [Iniziare con le più recenti ed elencare separatamente ciascun corso frequentato con successo/ Add separate entries for each relevant course you have completed, starting with the most recent. ] Nome e tipo d istituto di istruzione o formazione / Name and type of organisation providing education and training Principali materie e competenze professionali apprese / Principal subjects occupational skills covered Certificato o diploma ottenuto /Title of qualification awarded Livello nella classificazione nazionale o internazionale / Level in National classification October 17, 1995: Doctorate (Ph.D.) in Cellular and Molecular Biology and Pathology April 14, 1989: M. D. summa cum laude September 1989: License for medical practice in Italy University of Naples, Italy: Doctorate (Ph.D.) School of Medicine, "Federico II" University of Naples, Italy: M.D. Medicine, Biomedical Research M.D., Ph.D. N/A ATTIVITA DI RICERCA / RESEARCH ACTIVITIES Attuali campi di ricerca / Research sectors Recenti attività scientifiche/ Recent Scientific Activities. Autoimmune diseases Scientific research ULTERIORI INFORMAZIONI / ADDITIONAL INFORMATION Page 2 - Curriculum vitae

3 Pubblicazioni/ Books and Articles Elenco delle pubblicazioni realizzate negli ultimi 5 anni: Peer-reviewed publications: 1. Piao W-H, Jee YH, Liu RL, Coons SW, Kala M, Collins M, Young DA, Campagnolo DI, Vollmer TL, Bai X-F, La Cava A, Shi F-D IL-21 modulates CD4 + CD25 + regulatory T- cell homeostasis in experimental autoimmune encephalomyelitis. Scand. J. Immunol. 67: Singh RP, La Cava A, Hahn BH pconsensus peptide induces tolerogenic CD8 + T cells in lupus-prone (NZB x NZW)F1 mice by differentially regulating Foxp3 and PD1 molecules. J. Immunol. 180: Liu R, Bai Y, Vollmer TL, Bai X-F, Jee Y, Tang Y-Y, Campagnolo DI, Collins M, Young DA, La Cava A, Shi F-D IL-21 receptor expression determines the temporal phases of experimental autoimmune encephalomyelitis. Exp. Neurol. 211: Bai Y, Liu R, Huang D, La Cava A, Tiang YY, Iwakura Y, Campagnolo DI, Vollmer TL, Ransohoff RM, Shi F-D CCL2 recruitment of IL-6-producing CD11b + monocytes to the draining lymph nodes during the initiation of Th17-dependent B cell-mediated autoimmunity. Eur. J. Immunol. 38: Hahn BH, Anderson M, Le E, La Cava A Anti-DNA Ig peptides promote Treg cell activity in systemic lupus erythematosus patients. Arthritis Rheum. 58: Fenoglio D, Ferrera F, Fravega M, Balestra P, Battaglia F, Proietti M, Andrei C, Olive D, La Cava A, Indiveri F, Filaci G Advancements on phenotypic and functional characterization of non-antigen specific CD8 + CD28 - regulatory T cells. Hum. Immunol. 69: Wong M, Grossman J, Hahn BH, La Cava A Cutaneous vasculitis in breast cancer treated with chemotherapy. Clin. Immunol. 129:3-9 (featured on front cover). 8. Agrawal A, Lourenço EV, Gupta S, La Cava A Gender-based differences in leptinemia in healthy aging, non-obese individuals associate with increased marker of oxidative stress. Int. J. Clin. Exp. Med. 1: Lourenço EV, Procaccini C, Ferrera F, Iikuni N, Singh RP, Filaci G, Matarese G, Shi F-D, Brahn E, Hahn BH, La Cava A Modulation of p38 MAPK activity in regulatory T cells after tolerance with anti-dna Ig peptide in (NZB x NZW)F1 lupus mice. J. Immunol. 182: Iikuni N, Lourenço EV, Hahn BH, La Cava A Cutting edge: regulatory T cells directly suppress B cell in systemic lupus erythematosus. J. Immunol. 183: Singh RP, Dinesh R, Elashoff D, de Vos S, Rooney RJ, Patel D, La Cava A, Hahn BH Distinct gene signature revealed in white blood cells, CD4 + and CD8 + T cells in (NZB x NZW) F1 lupus mice after tolerization with anti-dna Ig peptide. Genes Immun. 11: Woo JM, Lin Z, Navab M, Van Dyck C, Trejo-Lopez Y, Woo KM, Li H, Castellani LW, Wang X, Iikuni N, Rullo OJ, Wu H, La Cava A, Fogelman AM, Lusis AJ, Tsao BP Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis. Arthritis Res. Ther. 12:R Liu R, Zhou Q, La Cava A, Campagnolo DI, Van Kaer L, Shi F-D Expansion of regulatory T cells via IL-2/anti-IL-2 mab complexes suppresses experimental myasthenia. Eur. J. Immunol. 40: Hahn BH, Lourenço EV, McMahon M, Skaggs B, Le E, Anderson M, Iikuni N, Lai C, La Cava A Pro-Inflammatory high density lipoproteins and atherosclerosis are induced in lupus-prone mice by a high fat diet and leptin. Lupus 19: Hao J, Liu R, Piao W, Zhou Q, Vollmer TL, Campagnolo DI, Xiang R, La Cava A, Van Kaer L, Shi F-D Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology. J. Exp. Med. 207: Wong M, La Cava A, Singh RP, Hahn BH Blockade of programmed death-1 in young (New Zealand Black x New Zealand White)F1 mice promotes the activity of suppressive CD8 + T cells that protect from lupus-like disease. J. Immunol. 185: Galgani M, Procaccini C, De Rosa V, Carbone F, Chieffi P, La Cava A, Matarese G Leptin modulates the survival of autoreactive CD4 + T cells through the nutrient/energysensing mammalian target of rapamycin signalling pathway. J. Immunol. 185: Procaccini C, De Rosa V, Galgani M, Abanni L, Calì G, Porcellini A, Carbone F, Fontana S, Horvath TL, La Cava A, Matarese G An oscillatory switch in mtor kinase activity sets regulatory T cell responsiveness. Immunity 33: Fiala M, Chattopadhay M, La Cava A, Tse E, Liu G, Lourenço E, Eskin A, Liu PT, Magpantay L, Tse S, Mahanian M, Weitzman R, Tong J, Nguyen C, Cho T, Koo P, Sayre J, Martinez-Maza O, Rosenthal MJ, Wiedau-Pazos M IL-17A is increased in the serum and in spinal cord CD8 and mast cells of ALS patients. J. Neuroinflamm. 7: Hao J, Campagnolo D, Liu R, Piao W, Shi S, Hu B, Xiang R, Zhou Q, Vollmer T, Van Kaer Page 3 - Curriculum vitae

4 L, La Cava A, Shi F-D Interleukin-2/interleukin-2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammation. Ann. Neurol. 69: Dinesh R, Hahn BH, La Cava A, Singh RP Interferon-inducible gene 202b controls CD8 + T cell-mediated suppression in anti-dna Ig peptide treated (NZB x NZW)F1 lupus mice. Genes Immun. 12: McMahon M, Skaggs BJ, Sahakian L, Grossman J, FitzGerald J, Ragavendra N, Charles- Schoeman C, Chernishof M, Gorn A, Witztum JL, Wong WK, Weisman M, Wallace DJ, La Cava A, Hahn BH High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids. Ann. Rheum. Dis. 70: Liu SD, Lee S, La Cava A, Motran CC, Hahn BH, Miceli C Galectin-1-induced downregulation of T-lymphocyte activation protects (NZB x NZW)F1 mice from lupus-like disease. Lupus 20: Yu Y, Liu Y, Shi F-D, Zou H, Hahn BH, La Cava A Tolerance induced by anti-dna Ig peptide in (NZB x NZW)F1 lupus mice impinges on the resistance of effector T cells to suppression by regulatory T cells. Clin. Immunol. 142: Liu Y, Yu Y, Matarese G, La Cava A Cutting edge: Fasting-induced hypoleptinemia expands functional regulatory T cells in systemic lupus erythematosus. J. Immunol. 188: Liu G, Fiala M, Mizwicki MT, Sayre J, Magpantay L, Siani A, Mahanian M, Chattopadhay M, La Cava A, Wiedau-Pazos M Neuronal phagocytosis by inflammatory macrophages in ALS spinal cord: inhibition of inflammation by resolvin D1. Am. J. Neurodegener. Dis. 1: Mizwicki MT, Fiala M, Magpantay L, Aziz N, Sayre J, Liu G, Siani A, Chan D, Martinez- Maza O, Chattopadhyay M, La Cava A Tocilizumab attenuates inflammation in ALS patients through inhibition of IL-6 receptor signaling. Am. J. Neurodegener. Dis. 1: Procaccini C, De Rosa V, Galgani M, Carbone F, Cassano S, Greco D, Qian K, Auvinen P, Calì G, Stallone G, Formisano L, La Cava A, Matarese G Leptin-induced mtor activation defines a specific molecular and transcriptional signature controlling CD4 + effector T cell responses. J. Immunol. 189: Wu W, Shi S, Ljunggren HG, La Cava A, Van Kaer L, Shi FD, Liu R NK cells inhibit T-bet-deficient, autoreactive Th17 cells. Scand. J. Immunol. 76: Wu Q, Yang Q, Sun H, Li M, Zhang Y, La Cava A Serum IFN-1 is abnormally elevated in rheumatoid arthritis patients. Autoimmunity 46: Galgani M, Nugnes R, Bruzzese D, Perna F, De Rosa V, Procaccini C, Mozzillo E, Cilio CM, Lernmark A, Larsson HE, La Cava A, Franzese A, Matarese G Metaimmunological profiling of children with type 1 diabetes identifies new biomarkers to monitor disease progression. Diabetes In press 32. Yu Y, Liu Y, Shi F-D, Zou H, Matarese G, La Cava A. Cutting edge: Leptin promotes IL-17 responses. J. Immunol. In press 33. Wong M, La Cava A, Hahn BH. Blockade of programmed death-1 (PD-1) in young (New Zealand Black x New Zealand White)F1 mice promotes the suppressive capacity of CD4 + regulatory T cells that protect from lupus-like disease. J. Immunol. In press Page 4 - Curriculum vitae Review articles: 1. Matarese G, De Rosa V, La Cava A Regulatory CD4 T cells: sensing the environment. Trends Immunol. 29: Ferrera F, Filaci G, Rizzi M, Singh RP, Indiveri F, Hahn BH, La Cava A New therapies in SLE. Recent Pat. Inflamm. Allergy Drug Discov. 2: Gianfrani C, Troncone R, La Cava A Autoimmunity and celiac disease. Mini Rev. Med. Chem. 8: La Cava A Natural Tregs in systemic lupus erythematosus. Curr. Immunol. Rev. 4: La Cava A T-regulatory cells in systemic lupus erythematosus. Lupus 17: Iikuni N, Lam QL, Lu L, Matarese G, La Cava A Leptin and inflammation. Curr. Immunol. Rev. 4: Singh RP, Hahn BH, La Cava A Tuning immune suppression in systemic autoimmunity with self-derived peptides. Inflamm. Allergy Drug Targets 7: La Cava A Tregs are regulated by cytokines: Implications for autoimmunity. Autoimmun. Rev. 8: Procaccini C, Lourenço EV, Matarese G, La Cava A Leptin signaling: A key pathway in immune responses. Curr. Signal Transduct. Ther. 4: Iikuni N, Hahn BH, La Cava A Potential for anti-dna immunoglobulin peptide therapy in systemic lupus erythematosus. Expert Opin. Biol. Ther. 9:

5 11. La Cava A Natural Tregs and autoimmunity. Front. Biosci. 14: La Cava A Immunotherapy with peptides in systemic lupus erythematosus. Curr. Med. Chem. 16: Lourenço EV, La Cava A Cytokines in systemic lupus erythematosus. Curr. Mol. Med. 9: La Cava A Lupus and T cells. Lupus 18: Cai C, La Cava A Mimicking self antigens with synthetic peptides in systemic autoimmune rheumatic diseases. Curr. Clin. Pharmacol. 4: Cai C, Shi F-D, Matarese G, La Cava A Leptin as clinical target. Recent Pat. Inflamm. Allergy Drug Discov. 3: Iikuni N, La Cava A Antibody-based therapies in systemic lupus erythematosus. Mini Rev. Med. Chem. 9: Cai C, Hahn BH, Matarese G, La Cava A Leptin in non-autoimmune inflammation. Inflamm. Allergy Drug Targets 8: La Cava A The busy life of regulatory T cells in systemic lupus erythematosus. Discov. Med. 8: Galgani M, Di Giacomo A, Matarese G, La Cava A The yin and yang of CD4 + regulatory T cells in autoimmunity and cancer. Curr. Med. Chem. 16: Dinesh RK, Skaggs BJ, La Cava A, Hahn BH, Singh RP CD8 + Tregs in lupus, autoimmunity, and beyond. Autoimmun. Rev. 9: Matarese G, Procaccini C, De Rosa V, Horvat TL, La Cava A Regulatory T cells in obesity: the leptin connection. Trends Mol. Med. 16: La Cava A Targeting B cells with biologics in systemic lupus erythematosus. Expert Opin. Biol. Ther. 10: Matarese G, Carrieri PB, Montella S, De Rosa V, La Cava A Leptin as a metabolic link to multiple sclerosis. Nat. Rev. Neurol. 6: La Cava A Modulation of autoimmunity with artificial peptides. Autoimmun. Rev. 10: La Cava A Laboratory medicine in pediatric lupus. J. Pediatr. Biochem. 1: La Cava A Anticytokine therapies in systemic lupus erythematosus. Immunotherapy 2: La Cava A, Fiala M Curcumin and immunity. Curr. Bioact. Comp. 6: La Cava A Regulatory immune cell subsets in autoimmunity. Autoimmunity 44: Lourenço EV, La Cava A Natural regulatory T cells in autoimmunity. Autoimmunity 44: Wong M, La Cava A Lupus, the current therapeutic approaches. Drug Today 47: Shi F-D, Ljunggren HG, La Cava A, Van Kaer L Organ-specific features of natural killer cells. Nat. Rev. Immunol. 11: Amarilyo G, Hahn BH, La Cava A Preclinical studies with synthetic peptides in systemic lupus erythematosus. Front. Biosci. 17: Liu Y, La Cava A Targeting BLyS in systemic lupus erythematosus. Recent Pat. Inflamm. Allergy Drug Discov. 6: Amarilyo G, La Cava A mirna in systemic lupus erythematosus. Clin. Immunol. 144: La Cava A The effects of curcumin on immune responses. Curr. Bioact. Comp. 8: La Cava A Proinflammatory activities of leptin in non-autoimmune conditions. Inflamm. Allergy Drug Targets 11: Matarese G, La Cava A, Horvath TL In vivo veritas, in vitro artificia. Trends Mol. Med. 18: La Cava A. Adiponectin: a relevant player in obesity-related colorectal cancer? Gut In press 40. Yu Y, La Cava A. Current drugs in systemic lupus erythematosus. Drug Develop. Res. In press 41. Wu Q, La Cava A. IL-17 in systemic lupus erythematosus. Clin. Invest. In press 42. La Cava A. Targeting the BLyS-APRIL signaling pathway in SLE. Clin. Immunol. In press Page 5 - Curriculum vitae Book chapters: 1. La Cava A Antibodies to DNA in systemic lupus erythematosus: A review and update. In Petrelli CT (Ed.): New research on autoantibodies. Nova Science Publishers, Hauppauge (New York). pp La Cava A, Hahn BH Immunotherapy with Ig-derived peptides in SLE: Current status and directions. In Seward TI (Ed.): Progress in systemic lupus erythematosus

6 research. Nova Science Publishers, Hauppauge (New York). pp La Cava A Regulatory T cells. In Pontell EB (Ed.): Immune tolerance research developments. Nova Science Publishers, Hauppauge (New York). pp Iikuni N, La Cava A Murine lupus models for the study of human systemic lupus erythematosus. In La Cava A. (Ed.): Recent research developments in rheumatology. Transworld Research Network, Trivandrum, pp La Cava A New developments in the management of systemic lupus erythematosus. In La Cava A (Ed.): Recent research developments in rheumatology. Transworld Research Network, Trivandrum, pp Hahn BH, Singh RR, Singh RP, Wong M, Skaggs B, Tsao BP, La Cava A Cellular regulation of autoimmunity. In Pisetsky D (Ed.): The American College of Rheumatology at 75: A diamond jubilee. John Wiley & Sons, Inc., Hoboken, pp La Cava A Immunotherapy with Ig-derived peptides in systemic lupus erythematosus. In Facinelli BC (Ed.): Immunotherapy: activation, suppression and treatments. Nova Science Publishers, Hauppauge, pp Mahanian M, Fiala M, Mizwicki M, La Cava A Immune modulation of inflammation in neurodegenerative diseases: Alzheimer s disease and amyotrophic lateral sclerosis. In Aggarwal (Ed.): Inflammation, life style and chronic diseases: the silent link. CRC Press, Taylor & Francis, Boca Raton, pp La Cava A Immunoregulatory cells in SLE. In Hahn BH and Wallace DJ (Ed.): Dubois Lupus Erythematosus. 8 th Edition. Lippincott Williams & Wilkins, New York, pp Books (Editor) : 1. Recent research developments in rheumatology. La Cava A. (Ed.) Transworld Research Network, Trivandrum. 2. An update on the pathogenesis of immune dysregulation in autoimmunity. La Cava A. (Ed.) vol ; Frontiers in Bioscience, New York. 3. Regulatory immune cell subsets in autoimmunity. La Cava A. (Ed.) Autoimmunity vol. 1; Informa Healthcare, New York. TRATTAMENTO DEI DATI PERSONALI, INFORMATIVA E CONSENSO Il D.Lgs. 30/6/2003, n. 196 Codice in materia di protezione dei dati personali regola il trattamento dei dati personali, con particolare riferimento alla riservatezza, all identità personale e al diritto di protezione dei dati personali; l interessato deve essere previamente informato del trattamento. La norma in considerazione intende come trattamento qualunque operazione o complesso di operazioni concernenti la raccolta, la registrazione, l organizzazione, la conservazione, la consultazione, l elaborazione, la modifica, la selezione, l estrazione, il raffronto, l utilizzo, l interconnessione, il blocco, la comunicazione, la diffusione, la cancellazione e la distruzione di dati, anche se non registrati in una banca dati. In relazione a quanto riportato, autorizzo il CNR al trattamento dei dati contenuti nel presente curriculum vitae e nella documentazione della quale fa parte integrante, sollevandolo da ogni responsabilità e autorizzandolo alla pubblicazione, nel sito web del CNR, della relazione inerente alle proprie ricerche svolte durante il soggiorno finanziato dal CNR nell ambito del Programma STM. Inoltre acconsento all aggiornamento delle informazioni intranet che mi riguardano sia relative le pubblicazioni sia alle ricerche svolte. ( barrare la casella) x Si, acconsento Prof. Antonio La Cava Page 6 - Curriculum vitae